Mammalian target of rapamycin as a target in hematological malignancies

Kevin R. Kelly, Julie H. Rowe, Swaminathan Padmanabhan, Steffan T. Nawrocki, Jennifer S. Carew

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)53-61
Number of pages9
JournalTargeted Oncology
Volume6
Issue number1
DOIs
StatePublished - Mar 1 2011

Keywords

  • Hematological malignancies
  • Novel agents
  • Targeted therapy
  • mTOR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Mammalian target of rapamycin as a target in hematological malignancies'. Together they form a unique fingerprint.

Cite this